PriceTargets.com logo

NASDAQ:MRSN - Mersana Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $28.17
  • Forecasted Upside: 235.72 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$8.39 As of 10/22/2021 03:51 PM ET
▼ -0.01 (-0.12%)

This chart shows the closing price for MRSN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mersana Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRSN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRSN

Analyst Price Target is $28.17
▲ +235.72% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Mersana Therapeutics in the last 3 months. The average price target is $28.17, with a high forecast of $33.00 and a low forecast of $18.00. The average price target represents a 235.72% upside from the last price of $8.39.

This chart shows the closing price for MRSN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Mersana Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/12/2021BTIG ResearchReiterated RatingBuyHigh
8/30/2021HC WainwrightInitiated CoverageBuy$28.00High
8/12/2021Robert W. BairdReiterated RatingBuy$30.00High
6/29/2021BTIG ResearchReiterated RatingBuy$32.00High
3/30/2021Credit Suisse GroupInitiated CoverageNeutral$18.00High
12/2/2020Stifel NicolausInitiated CoverageBuy$33.00High
11/9/2020SVB LeerinkBoost Price TargetOutperform$25.00 ➝ $28.00Medium
9/29/2020JPMorgan Chase & Co.Initiated CoverageNeutralMedium
6/24/2020BTIG ResearchBoost Price TargetBuy$21.00 ➝ $32.00Low
6/23/2020HC WainwrightReiterated RatingBuy$26.00Low
5/28/2020Robert W. BairdBoost Price TargetOutperform$12.00 ➝ $20.00High
5/27/2020SVB LeerinkBoost Price TargetOutperform$12.00 ➝ $21.00High
5/27/2020HC WainwrightBoost Price TargetBuy$13.00 ➝ $26.00High
4/29/2020BTIG ResearchInitiated CoverageBuy$14.00High
3/2/2020HC WainwrightReiterated RatingBuy$13.00High
2/11/2020HC WainwrightReiterated RatingBuy$12.00High
1/21/2020HC WainwrightBoost Price TargetBuy$7.00 ➝ $12.00High
1/13/2020CowenReiterated RatingBuyHigh
1/10/2020HC WainwrightReiterated RatingBuy$7.00High
11/7/2019HC WainwrightReiterated RatingBuy$7.00Low
6/2/2019CowenReiterated RatingBuyHigh
3/11/2019JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
3/8/2019Robert W. BairdSet Price TargetBuy$12.00High
1/4/2019HC WainwrightSet Price TargetBuy$14.00High
11/28/2018HC WainwrightSet Price TargetBuy$23.00High
11/14/2018HC WainwrightSet Price TargetBuy$23.00Low
11/14/2018SVB LeerinkUpgradeMarket Perform ➝ OutperformLow
9/18/2018WedbushBoost Price TargetOutperform$15.00 ➝ $16.00High
9/17/2018HC WainwrightBoost Price TargetHold ➝ Buy$11.06 ➝ $23.00High
8/16/2018HC WainwrightSet Price TargetBuy$16.00High
8/15/2018Robert W. BairdSet Price TargetBuy$20.00Medium
7/20/2018SVB LeerinkReiterated RatingOverweight ➝ Market Perform$61.00Medium
7/20/2018HC WainwrightSet Price TargetHold ➝ Buy$16.00High
7/19/2018SVB LeerinkDowngradeOutperform ➝ Market Perform$61.00High
6/6/2018HC WainwrightSet Price TargetBuy$33.00High
5/15/2018HC WainwrightSet Price TargetBuy$33.00Medium
5/7/2018Robert W. BairdInitiated CoverageOutperform ➝ Outperform$30.00High
4/25/2018HC WainwrightSet Price TargetBuy$33.00High
4/17/2018HC WainwrightSet Price TargetBuy$33.00Medium
4/16/2018CowenReiterated RatingBuyMedium
3/29/2018HC WainwrightSet Price TargetBuy$33.00Medium
3/28/2018SVB LeerinkReiterated RatingOutperformHigh
3/19/2018HC WainwrightSet Price TargetBuy$33.00High
3/19/2018JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$23.00High
3/2/2018HC WainwrightSet Price TargetBuy$33.00Medium
2/15/2018HC WainwrightInitiated CoverageBuyMedium
7/24/2017WedbushReiterated RatingOutperform ➝ Outperform$25.00High
7/24/2017SVB LeerinkInitiated CoverageOutperform ➝ Outperform$23.00High
7/24/2017JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$23.00High
7/24/2017CowenInitiated CoverageOutperformHigh
(Data available from 10/22/2016 forward)

News Sentiment Rating

-0.10 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2021

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Mersana Therapeutics logo
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing antibody drug conjugates that offer clinical benefit for cancer patients with significant unmet need. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $8.39
Low: $8.07
High: $8.44

50 Day Range

MA: $10.81
Low: $8.35
High: $14.47

52 Week Range

Now: $8.39
Low: $8.16
High: $29.09

Volume

19,551 shs

Average Volume

506,412 shs

Market Capitalization

$602.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Mersana Therapeutics?

The following Wall Street research analysts have issued stock ratings on Mersana Therapeutics in the last year: BTIG Research, Credit Suisse Group AG, HC Wainwright, Robert W. Baird, Stifel Nicolaus, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for MRSN.

What is the current price target for Mersana Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Mersana Therapeutics in the last year. Their average twelve-month price target is $28.17, suggesting a possible upside of 235.3%. Stifel Nicolaus has the highest price target set, predicting MRSN will reach $33.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $18.00 for Mersana Therapeutics in the next year.
View the latest price targets for MRSN.

What is the current consensus analyst rating for Mersana Therapeutics?

Mersana Therapeutics currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MRSN will outperform the market and that investors should add to their positions of Mersana Therapeutics.
View the latest ratings for MRSN.

What other companies compete with Mersana Therapeutics?

Other companies that are similar to Mersana Therapeutics include Pacira BioSciences, Erasca, Harmony Biosciences, ATA, Indivior, Xencor, Ligand Pharmaceuticals, Turning Point Therapeutics, Corcept Therapeutics, ALX Oncology, Dynavax Technologies, Ironwood Pharmaceuticals, Evotec, Nuvation Bio and Verve Therapeutics.

How do I contact Mersana Therapeutics' investor relations team?

Mersana Therapeutics' physical mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company's listed phone number is (617) 498-0020 and its investor relations email address is [email protected] The official website for Mersana Therapeutics is www.mersana.com.